CAR‑T therapies have reshaped what’s possible in oncology, offering targeted, durable responses in diseases where conventional treatments often fall short. But their behaviour inside the body is fundamentally different from that of small molecules or biologics — and that difference has major implications for how sponsors design, analyse, and interpret pharmacokinetic (PK) studies.
Traditional PK frameworks assume predictable absorption, distribution, metabolism, and excretion. CAR‑T cells don’t follow those rules. They expand, contract, migrate, persist, and sometimes reactivate — all in response to the biology of the patient and the tumour. Understanding these dynamics is essential for designing meaningful early‑phase studies and for building a development plan that regulators will accept.
This piece outlines the core principles of CAR‑T cellular kinetics and what sponsors need to consider when planning PK assessments for these advanced therapies.
After infusion, CAR‑T cells don’t behave like a drug entering systemic circulation. Once they encounter their target antigen, they activate and expand — often dramatically — reaching peak concentrations one to two weeks after dosing.
This expansion is influenced by factors such as:
tumour burden
antigen availability
prior therapies
patient‑specific immune status
manufacturing variability
As a result, the concentration of CAR‑T cells in blood is not directly proportional to the administered dose. Two patients receiving the same dose may show entirely different expansion profiles.
Unlike conventional therapeutics, CAR‑T cells can persist for months or even years. Their presence — or absence — over time can signal:
durability of response
risk of relapse
potential for reactivation
long‑term safety considerations
Regulators expect sponsors to monitor CAR‑T levels long after the initial treatment window, and to interpret those data in the context of clinical outcomes.
CAR‑T PK profiles are inherently variable. It’s common to see:
quantification fluctuations
multiple peaks due to reactivation
delayed expansion in some patients
no expansion at all when the target antigen is absent
This variability isn’t noise — it’s biology. Study designs must anticipate it, and analytical plans must be flexible enough to capture meaningful patterns without forcing CAR‑T behaviour into traditional PK models.
Because CAR‑T cells are living entities, PK assessments rely on specialised methods such as:
quantitative PCR to measure transgene levels
flow cytometry to characterise phenotype and viability
modelling approaches that integrate cellular kinetics with clinical endpoints
These tools allow developers to track expansion, persistence, and reactivation — the hallmarks of CAR‑T behaviour — and to link them to safety and efficacy.
For CAR‑T therapies, PK cannot be separated from:
mechanism of action
tumour biology
patient characteristics
manufacturing attributes
clinical response
Regulators want to see a coherent narrative: how the product behaves, why it behaves that way, and what that means for dose selection, safety monitoring, and long‑term follow‑up.
A strong PK strategy doesn’t just generate data — it explains the biology.
CAR‑T development touches every part of early‑phase science: CMC, non‑clinical design, clinical pharmacology, biostatistics, and regulatory strategy. When these functions operate independently, important connections are missed — and those gaps can slow development or weaken submissions.
An early‑phase specialist ecosystem brings these disciplines together. Analytical scientists, clinical pharmacologists, statisticians, regulatory experts, and operational teams work as a single unit, interpreting CAR‑T kinetics in the context of manufacturing, patient biology, and clinical outcomes.
For sponsors, this integration is critical. It ensures that PK data are meaningful, that study designs reflect real‑world CAR‑T behaviour, and that regulatory interactions are grounded in a deep understanding of how these therapies work.
CAR‑T therapies don’t behave like traditional drugs — and their PK profiles shouldn’t be treated as if they do. Sponsors who understand the principles of cellular kinetics, anticipate variability, and build PK strategies around the biology move more confidently through early development.
And those who partner with an early‑phase specialist ecosystem gain something even more important: a coordinated team that can interpret CAR‑T behaviour across scientific, clinical, and regulatory dimensions, creating a clearer, more reliable path from first‑in‑human to proof‑of‑concept.